A 52-year-old man with newly diagnosed multiple myeloma presents to the oncology clinic. He is planned for induction therapy with bortezomib and dexamethasone followed by high-dose melphalan with autologous stem cell transplantation. Before initiating melphalan, which investigation is most appropriate to assess the risk of treatment-related toxicity and guide dose modification?